目的 探究百令膠囊聯(lián)合來(lái)氟米特片和醋酸潑尼松片治療狼瘡性腎炎的臨床療效。方法 選取2012年12月—2017年3月開封市中心醫(yī)院收治的126例狼瘡性腎炎患者作為研究對(duì)象，按隨機(jī)原則將患者分為對(duì)照組（63例）和治療組（63例）。對(duì)照組患者口服來(lái)氟米特片，2片/次，1次/d；同時(shí)口服醋酸潑尼松片，1 mg/(kg·d)，2個(gè)月后減量至10 mg/d。治療組在對(duì)照組的基礎(chǔ)上口服百令膠囊，1 g/次，3次/d。兩組患者均連續(xù)治療6個(gè)月。觀察兩組患者的臨床療效，同時(shí)比較治療前后兩組的白蛋白（ALB）、血肌酐（Scr）、24 h尿蛋白定量（24 h UP）、補(bǔ)體C3、紅細(xì)胞（RBC）和β₂-微球蛋白（β₂-MG）水平、系統(tǒng)性狼瘡性疾病活動(dòng)度（SLEDAI）積分。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為79.37%、92.06%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組ALB、補(bǔ)體C3和RBC較治療前明顯升高，而Scr、24 h UP和β₂-MG較治療前明顯下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組ALB、補(bǔ)體C3和RBC較對(duì)照組明顯升高，Scr、24 h UP和β₂-MG較對(duì)照組明顯下降，兩組比較差異具統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組SLEDAI積分較治療前明顯下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療后，治療組SLEDAI積分較對(duì)照組顯著降低，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 百令膠囊聯(lián)合來(lái)氟米特片和醋酸潑尼松片治療狼瘡性腎炎具有較好的臨床療效，可改善腎臟功能，降低狼瘡性腎炎活動(dòng)度和不良反應(yīng)發(fā)生率，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical efficacy of Corbrin Capsules combined with Leflunomide Tablets and Prednisone Acetate Tablets in treatment of lupus nephritis. Methods Patients (126 cases) with lupus nephritis in Kaifeng Central Hospital from December 2012 to March 2017 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Leflunomide Tablets, 2 tablets/time, once daily. At the same time, they were po administered with Prednisone Acetate Tablets, 1 mg/(kg∙d), and reduced to 10 mg/d after 2 month. Patients in the treatment group were po administered with Corbrin Capsules on the basis of the control group, 1 g/time, three times daily. Patients in two groups were treated for 6 month. After treatment, the clinical efficacy was evaluated, and ALB, Scr, 24 h UP, complement C3, RBC, and β₂-MG levels, and the SLEDAI scoresin two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 79.37% and 92.06%, respectively, and there were differences between two groups (P<0.05). After treatment, ALB, complement C3, and RBC were significantly increased in two groups, but Scr, 24 h UP, and β₂-MG were significantly decreased, and there were differences in the same group (P<0.05). After treatment, ALB, complement C3, and RBC levels in the treatment group were higher than those in the control group, but Scr, 24 h UP, and β₂-MG were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, SLEDAI scores in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, SLEDAI scores in the treatment group were significantly lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Corbrin Capsules combined with Leflunomide Tablets and Prednisone Acetate Tablets has clinical curative effect in treatment of lupus nephritis, can improve renal function and reduce activity and incidence of adverse reaction, which has a certain clinical application value.

開封市科技發(fā)展計(jì)劃項(xiàng)目（1603007）